TNFRSF8 and diffuse large B-cell lymphoma: On the other hand, drugs already approved in other indications such as the conjugated anti-CD30 antibody brentuximab [33,34] and the T-cell checkpoint inhibitor pembrolizumab [35] appear to be very effective in certain subtypes of DLBCL.